Medication Treatments

Stimulant Summit: Providers Must Weather Storm as COVID Complicates Stimulant Surge
With the lethality, availability and use of stimulants all greatly increasing in the U.S. in recent years and the COVID-19 pandemic complicating the treatment landscape for patients and practitioners alike, it’s critical for providers to weather the storm, Deni Carise, PhD, chief science officer for Recovery Centers of America, told Cocaine, Meth & Stimulant Summit attendees in a Saturday session.
Indiana University Researchers to Study Use of Tezampanel for Opioid Withdrawal
The Indiana University School of Medicine has received a $12.3 million grant from the National Institute on Drug Abuse for a two-stage research project to study the use of tezampanel to treat opioid withdrawal syndrome, as well as other addictions and mental illnesses.
MAT Pharmacy Program Expands to Arizona
Cordant Health Solutions has added a pharmacy in Mesa, Arizona, that will collaborate with clinicians in OBOT settings to deliver medicines to patients during their office visits.
Clinicians Prescribing Buprenorphine Far Below Limits of Waivers
Half of clinicians who are waivered to prescribe buprenorphine for the treatment of opioid use disorder have actually done so, and a majority are prescribing the medication for a number of patients that is well below the limit for which they are waivered, according to a new study.
Pregnant Women Shown to Face Additional Barriers to OUD Treatment in Study
A study using trained actors attempting to get addiction treatment in 10 states found that pregnant women were about 20% less likely to be accepted for treatment vs. women who are not pregnant, with the largest discrepancy involving buprenorphine prescribers.
FDA Seeks Public Input on Patient-Focused Drug Development for Stimulant Use Disorder
The FDA will conduct a virtual public meeting on patient-focused drug development for stimulant use disorder on Oct. 6, and is seeking input from individuals and families impacted by stimulant use.
Temple Researchers Receive NIDA Grant to Study Cocaine Addiction Treatment
Researchers at Temple University have received a $1.77 million grant from the National Institute on Drug Abuse to study the effects of a therapy for the treatment of cocaine use disorder, according to a media report.
1 in 5 Emergency Dept. Physicians Ready to Offer Buprenorphine
A Yale study of 400 clinicians found that just 21% of emergency department clinicians say they are prepared to prescribe buprenorphine for the treatment of opioid use disorder.
Elevate Spotlight: Best Practices in Opioid Addiction Treatment
With the far reach of the opioid epidemic and the high comorbidity of opioid addiction with other psychiatric disorders, the session will be relevant to all attendees, not just those in addiction medicine.
NCAD West: Prescription Opioid Misuse Drops, but Providers Need to Stay Vocal
During the opening plenary of NCAD West on Thursday, Colorado Consortium for Prescription Drug Abuse director Rober Valuck, PhD, RPh, FNAP, implored attendees to aggressively fight barriers to treatment, scrutinize their own work, and learn from their peers.
NCAD West: Focus on Function When Treating Chronic Pain
Las Vegas Recovery Center chief medical officer Mel Pohl, MD, DFASAM, shared risks of using opioids to treat chronic pain and offered non-medication alternatives to improve patients’ ability to function on Thursday at NCAD West.
Back to Top